Dear Investor,

In August, the chairman of the CFTC stood in front of a room in Washington and laid out his marching orders...

He said the agency would heed President Trump's call to build a digital asset market structure that "cannot be undone by the crypto haters."

Then he told the room he had already directed his staff to begin writing the rules.

That was six weeks before the Senate vote on the Clarity Act.

Most investors completely missed it.

Because everyone was watching Congress. The Clarity Act. The whip counts. The odds on prediction markets.

And on September 15th, the bill failed.

For about a day, the headlines called it a disaster for crypto.

Then something else happened...

Three days later, the CFTC filed its own crypto framework with the White House budget office. The SEC already had its rules out for public comment. Both agencies are run by men this president appointed for precisely this purpose.

The CFTC chairman had said it plainly back in August: "We owe it to the American people to do so."

The bill was the slow road... this was always the fast one.

One coin sits at the center of this shift, playing the infrastructure role Uniswap and PancakeSwap played early on, except this one has federal policy pushing behind it.

Smart money is accumulating. Volume is hitting record highs. And the market cap is still under $2 billion.

My team broke the whole thing down:

Get my #1 altcoin for the Trump-powered bull run.

To your massive success,

Bryce Paul
Crypto 101

Bond Yields Are Pressuring Gold, But Miners May Tell a Different Story

Authored by Jeffrey Neal Johnson. Date Posted: 9/8/2026.

Investors tracking precious metals face a shifting macroeconomic landscape. The historical relationship between geopolitical tension and asset prices is evolving under pressure from a global bond market sell-off. As energy-driven inflation fears push long-term U.S. Treasury yields toward multiyear highs, this high-rate environment creates distinct headwinds for nonyielding assets.

Beneath the retail market volatility, sovereign entities are implementing substantial wealth-preservation strategies. Central banks continue to buy gold, while some are also reassessing where they store their physical bullion. The tension between institutional demand for physical security and the higher-rate macroeconomic headwind has left gold-mining equities trading at a noticeable discount to their underlying fundamentals. For market participants evaluating a strategic hedge against fiat-currency depreciation, this disconnect highlights an under-the-radar opportunity in the equity markets.

Taming the Yield Curve With Physical Assets

SpaceX's march to $10 trillion (Ad)

SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation.

But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly.

An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151.

See the full story on this SpaceX-linked stock now

The broader macroeconomic narrative is currently dominated by fixed-income volatility. With the 10-year U.S. Treasury yield hovering around 4.8% and the 30-year yield above approximately 5.25%, capital naturally flows toward risk-adjusted returns. Recent Middle East escalations initially pressured gold, as rising oil prices reinforced inflation expectations and kept central banks committed to restrictive monetary policies. High interest rates increase the opportunity cost of holding physical commodities, creating a challenging near-term environment for spot prices.

The institutional response to this geopolitical instability tells a different story. The Dutch Central Bank recently finalized the logistical transfer of 86 tonnes of physical gold from New York and Ottawa to London and Zeist. The move prioritizes tradability, availability and crisis readiness, signaling growing sovereign anxiety about fiat-currency stability.

When sovereign entities prioritize physical possession over paper claims, it can help establish a structural floor for the underlying commodity, even as high yields create temporary friction for broader retail accumulation. The physical market is tightening, setting the stage for a fundamental repricing of the companies that extract these assets.

Unearthing Cash Flow Over Macro Noise

While physical supply tightens, mining equities are trading as if the mining sector is entering a prolonged contraction. This creates a quantifiable valuation gap. Top-tier operators demonstrate margin resilience that remains largely unpriced by the broader market. On a purely fundamental basis, these businesses are generating cash at a rate that belies their current trading multiples.

Newmont Corporation (NYSE: NEM) currently trades near $130 per share, supported by a net margin approaching 33.36%.

The business generates about $9.93 in cash flow per share, comfortably navigating the higher costs associated with modern extraction, energy and labor.

Despite generating more than $22 billion in annual sales, Newmont Corporation maintains a compressed forward price-to-earnings ratio of about 14.49.

This valuation suggests the market is pricing in peak operating costs without fully accounting for the structural floor being established in the spot market.

Similarly, Barrick Mining (NYSE: B) exhibits fundamental strength that defies its recent price consolidation.

Trading around $45, Barrick Mining reported a revenue increase of approximately 43.8% year over year in its latest quarter.

Barrick Mining operates with a net margin near 31.60% and generates about $3.82 in cash flow per share. With a forward price-to-earnings ratio of 12.82, the equity offers a distinct discount relative to its operational efficiency.

Both Newmont Corporation and Barrick Mining maintain debt-to-equity ratios below 0.16, helping insulate their balance sheets from the interest-rate shocks currently rattling the broader market.

Strategic Consolidation on the Gold Frontier

When capital costs rise across the broader economy, a management team's capital-allocation strategy becomes a primary driver of shareholder returns. The contrast between these two operators offers distinct avenues for portfolio integration, allowing investors to tailor their exposure to income preferences and growth expectations.

Barrick Mining places a heavy emphasis on direct shareholder returns. The business anticipates approximately 14.33% forward earnings growth and supports a moderate dividend yield of about 1.53%. Management authorized a $3 billion stock repurchase program in May 2026 that is intended to run through early 2027, allowing for the open-market retirement of up to 3.2% of outstanding shares.

Barrick's buyback effectively uses excess free cash flow to establish a synthetic bid for its stock during periods of macro-driven weakness. Barrick Mining is reportedly considering delaying the initial public offering of its North American gold business until 2027. This possible delay would push back the timeline for unlocking the value of specific regional assets while allowing Barrick Mining to retain full cash-flow generation from those properties during a period of significant macroeconomic uncertainty.

Newmont Corporation is focusing heavily on structural consolidation and operational reinvestment. Newmont Corporation recently made a $1.95 billion cash payment to Barrick Mining to finalize a Nevada Gold Mines joint-venture settlement.

This strategic payment secures full control of a highly productive asset base, streamlining operations in one of the world's most prolific mining jurisdictions. While Newmont Corporation offers a lower dividend yield of about 0.80%, the transaction positions Newmont Corporation to scale production efficiently as global supply constraints tighten.

Smart Money Strikes a Valuation Arbitrage

Retail investors often overlook the mechanics of institutional and passive liquidity, which can act as a delayed catalyst for fundamentally sound equities. Both Newmont Corporation and Barrick Mining maintain healthy institutional ownership and short-interest levels, indicating that current market positioning reflects a combination of long-term accumulation and ongoing skepticism.

Heavy institutional concentration supports this structural thesis. The California State Teachers Retirement System holds an approximate 14.74% stake in Newmont Corporation, followed by BlackRock at roughly 11%. These large allocations suggest that major asset managers are using Newmont Corporation as a leveraged, dividend-paying instrument to hedge against sovereign-debt risks.

While insider data show that the chief executive officer of Newmont Corporation executed a 7,764-share sale in early August and an executive vice president sold approximately $280,000 in stock, the significant institutional ownership provides a stabilizing counterweight to these routine executive liquidity events.

Passive exchange-traded fund flows offer a persistent structural tailwind for both businesses. As capital rotates back into commodities to hedge against persistent inflation, major index funds programmatically allocate capital to heavily weighted constituents such as Newmont Corporation and Barrick Mining, creating a steady baseline of market demand regardless of day-to-day retail sentiment.

Forging Ahead in a Yield-Starved Market

The tension between rising bond yields and sovereign gold accumulation creates a unique environment for equities tied to precious metals. While high interest rates pose a near-term headwind for the underlying physical commodity, miners themselves operate as highly profitable businesses. Their ability to generate steady free cash flow, maintain double-digit net margins and execute billion-dollar share repurchases may not be fully reflected in their current market multiples.

Investors navigating the ongoing global debt rout might consider adding these discounted producers to their portfolios. Those seeking direct shareholder returns and higher forward earnings growth may find Barrick Mining's buyback program and dividend yield attractive. Investors focused on large-scale asset consolidation and jurisdictional dominance might favor Newmont Corporation's strategic market positioning. Cautious market participants may prefer to monitor the 10-year U.S. Treasury yield for signs of stabilization before establishing a long-term position in the sector.

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Authored by Chris Markoch. Date Posted: 9/13/2026.

For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or FDA decision.

When that moment arrives, there's rarely a middle ground: a positive result can send shares sharply higher and validate years of spending, while a miss can wipe out most of the market cap overnight. That's what makes these "binary catalysts" so important to track—and so risky to hold through.

SpaceX's march to $10 trillion (Ad)

SpaceX just signed a deal JPMorgan says could unlock the next phase of the space economy, putting the company on a path toward a 10 trillion valuation.

But analyst Dylan Jovine says the biggest winner won't be SpaceX itself. He's identified a small firm, less than half a percent SpaceX's size, that partnered with it directly.

An upcoming NASA announcement could be the catalyst. Jovine previously flagged Rocket Lab before it climbed from under 4 dollars to over 151.

See the full story on this SpaceX-linked stock now

Below are three small-cap biotechs facing exactly that kind of moment before the end of 2026. Each has a different disease, drug and timeline, but all three share the same setup: one event, largely beyond the company's control, that could reset the stock's trajectory with a single announcement.

Kodiak Sciences: A Wet AMD Verdict That Could Reset the Balance Sheet

Kodiak Sciences (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases. What's driving interest in KOD in late 2026 is the expected release of results from the company's Phase 3 DAYBREAK study.

DAYBREAK is testing two of Kodiak's drug candidates, Zenkuda and KSI-501, in patients who have never been treated for wet age-related macular degeneration (wet AMD). Wet AMD is a leading cause of vision loss in which abnormal blood vessels leak fluid behind the retina.

Because each drug is being evaluated separately against aflibercept, the current standard of care, DAYBREAK is effectively two readouts packaged into one headline event. Both comparisons test whether Kodiak's candidates can match aflibercept's vision and safety outcomes while requiring fewer eye injections over the course of a year, with roughly 690 patients enrolled across the two studies.

It isn't hyperbolic to say that these clinical trial results, which are due between September and December 2026, represent a make-or-break moment for KOD shareholders. Drug development is expensive, and Kodiak's net loss in Q2 2026 widened to $65.6 million, compared with a $54.3 million loss in the prior year.

That comes at a time when the company has reported significant year-over-year reductions in working capital and stockholders' equity. Kodiak ended the quarter with $125.9 million in cash and equivalents, which management says will cover operations into 2027.

Positive DAYBREAK results would help mitigate balance-sheet concerns. Analysts are bullish on that possibility. The analyst forecasts on MarketBeat show a consensus Moderate Buy rating with a $48.14 price target, representing a 48% gain from recent prices.

Capricor Therapeutics: A Delayed FDA Decision Still Looms Large

Capricor Therapeutics (NASDAQ: CAPR) is another clinical-stage biotech. The company focuses on developing cell- and exosome-based therapeutics for cardiovascular and rare diseases.

Capricor's leading drug candidate is Deramiocel, which is being developed to treat Duchenne muscular dystrophy. The drug is under review by the U.S. Food and Drug Administration, which has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel from Aug. 22 to Nov. 22, 2026.

This came after Capricor submitted an additional two years of follow-up data from its pivotal HOPE-3 study in support of a narrower, upper-limb-focused indication. Regulators classified the new data as a major amendment, triggering the three-month delay. However, the underlying decision itself hasn't changed; it has simply been pushed to late November.

The consensus price target from analysts tracked by MarketBeat for CAPR is $29.15, which would represent more than 230% upside from recent prices.

Invivyd: Betting on a Next-Generation COVID Shield

Invivyd (NASDAQ: IVVD) focuses on discovering, developing and commercializing antibody-based solutions for infectious diseases. What makes Invivyd different from the other two names in this article is that the company has a commercially available product, PEMGARDA, a long-acting monoclonal antibody for the pre-exposure prophylaxis of COVID-19. The drug targets immunocompromised patients whose bodies don't mount an adequate response to vaccination.

The immediate catalyst for Invivyd is the DECLARATION study, a pivotal Phase 3 trial for VYD2311. The drug is essentially a next-generation, longer-acting successor to PEMGARDA aimed at the same immunocompromised population.

The trial has three arms—a single dose of VYD2311, a multidose regimen and a placebo—and has already earned FDA Fast Track designation. Enrollment is complete, and the study is approaching its planned analysis. Invivyd plans to hold a dedicated investor call once results are available rather than folding the news into a routine earnings report.

Success would provide the company with an expanded label for treating COVID-19. The company also has other pipeline candidates in earlier clinical trial phases that could position it to address a range of additional conditions, including measles, mumps, rubella and Lyme disease.

IVVD is a true penny stock, trading for just 81 cents per share as of this writing. However, analysts have a consensus price target of $8. That price target is supported by HC Wainwright and Cantor Fitzgerald, both of which have reiterated Buy or equivalent ratings since the company's Q2 2026 earnings report in August.